TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03075059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Life
Description: For patients randomized to the intervention group, the Child Life specialist will reach out via telephone to offer support and expertise in helping prepare their child and themselves for outpatient surgery to help decrease anxiety and increase coping. Concepts covered will include: developmentally appropriate language for explaining surgery and related procedures, potential coping skills to ease separation for caregivers and pediatric patients. Additionally, written materials (attached) covering the same information will be sent via mail or email covering the same information discussed in the phone conversation to serve as a refresher and resource before the day of surgery. On the day of surgery, the patient will receive standard of care (SOC) Child Life Services available to all patients.
Study: NCT00462280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lovastatin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lovastatin
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: biopsy
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: biopsy
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04859582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as an IV infusion on Day 1 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered as an IV infusion on Day 1 Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered as an IV infusion on Day 1 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Administered as a continuous IV infusion on Days 1-5 Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Administered as a continuous IV infusion on Days 1-5 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered as an IV infusion on Day 1 Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Administered as an IV infusion on Day 1 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered orally BID on Days 1 to 14 Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Administered orally BID on Days 1 to 14 Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Pembrolizumab
Description: Administered as an IV infusion on Day 1 Q3W
Study: NCT01303081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Rewards
Description: If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fixed Deposits
Description: Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chosen Deposits
Description: Participants will choose their deposit amount (XX = chosen deposit); this same amount will be returned upon success (that is, quit smoking by the target quit date, and having this confirmed by cotinine/anabasine tests). If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. The default deposit will be set to a certain monetary amount for consistency with other arms, and participants can increase or decrease this amount until they reach the amount they want to deposit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competitive Deposits (Pari-Mutuel)
Description: Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, and the payout for quitting on this arm will be Y x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days and 3 months (among those eligible).
Study: NCT01622010

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Allied Health Education Class Option
Description: An Allied Health Education Class is provided as part of standard care on an optional basis. It involves a one time attendance at a 90 minute class which provides basic education from a multidisciplinary team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Allied Health Education Class Option
Description: An Allied Health Education Class is provided as part of standard care on an optional basis. It involves a one time attendance at a 90 minute class which provides basic education from a multidisciplinary team.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy treatment intervention on referral
Description: The option exists for referral to physiotherapy, according to standard protocol, for assessment and individual exercise prescription.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment intervention on referral
Description: The option exists for referral to physiotherapy, according to standard protocol, for assessment and individual exercise prescription.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Keeping the Beat with Physiotherapy: Heart Failure edition
Description: Educational DVD covering the basics of physiotherapy education for the patient with heart failure.
Study: NCT01226901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4827
Description: MK-4287, 150 mg or 300 mg capsule, orally, once daily in 21 day cycles.
Study: NCT01875939

Intervention type: DRUG
Group type: OTHER
Intervention: Oral WCK2349
Description: The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.

Intervention type: DRUG
Group type: OTHER
Intervention: IV WCK771
Description: The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
Study: NCT00524914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apomorphine
Description: Acute apomorphine subcutaneous 3 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo subcutaneous
Study: NCT00584935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15).
Study: NCT02112916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT, IV, or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT, IV, or SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone Sodium Succinate
Description: Given IT
Study: NCT04121156

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD-tDCS treatment
Description: 2 milli Amp dose of HD-tDCS treatment for for 20 minutes, for 5 consecutive twice daily sessions

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham (placebo) HD-tDCS
Description: Participants will receive sham (placebo) HD-tDCS for 20 minutes, for 5 consecutive twice daily sessions
Study: NCT04270071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yangxin Shengmai
Description: Yangxin Shengmai Granules
Study: NCT02112916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Sodium Succinate
Description: Given IT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Give PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Give PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT, IV, or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV, or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT01054261

Intervention type: DRUG
Group type: OTHER
Intervention: avanafil
Description: 200 mg avanafil tablet QD

Intervention type: DRUG
Group type: OTHER
Intervention: avanafil
Description: 200 mg avanafil tablet QD

Intervention type: DRUG
Group type: OTHER
Intervention: avanafil
Description: 200 mg avanafil tablet QD
Study: NCT04200911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamune
Description: Sirolimus 1mg capsules
Study: NCT00286793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-101
Description: Oral
Study: NCT04885933

Intervention type: DIAGNOSTIC_TEST
Intervention: sarcopenia measurement
Description: BIA for fat free muscle mass hand grasp strength
Study: NCT00681304

Intervention type: OTHER
Intervention: ultrasound scan
Description: The only study procedure involved in this project is for subjects to undergo an ultrasound scan during their radiation therapy simulation. The ultrasound is done at this time, so it can be co-registered to the routine breast treatment planning CT scan.
Study: NCT03839732

Intervention type: DIAGNOSTIC_TEST
Intervention: Score of abdominal aorta calcifications
Description: Radiographs showing VC will be used to assess whether the computer assisted VC scoring (primary objective) and Quantitative Vertebral Morphometry (QVM, limited to lumbar spine, secondary objective n.1) through the Calcify2D software are less variable with respect to the traditional visual scoring of VC and QVM.
Study: NCT04270071

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yangxin Shengmai placebo
Description: Yangxin Shengmai placebo have an identical appearance and scent as the active treatment granules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nitroglycerin tablets
Description: Be used when angina attack
Study: NCT01651403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir DF
Description: * Participants weighing ≥ 17 kg will receive TDF one tablet administered orally once daily (150, 200, 250 or 300 mg tablets based on body weight).~* Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF oral powder in a dose of 8 mg/kg once daily up to a maximum dose of 300 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir DF
Description: * Participants weighing ≥ 17 kg will receive TDF one tablet administered orally once daily (150, 200, 250 or 300 mg tablets based on body weight).~* Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF oral powder in a dose of 8 mg/kg once daily up to a maximum dose of 300 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir DF
Description: * Participants weighing ≥ 17 kg will receive TDF one tablet administered orally once daily (150, 200, 250 or 300 mg tablets based on body weight).~* Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF oral powder in a dose of 8 mg/kg once daily up to a maximum dose of 300 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TDF Placebo
Description: * Participants weighing ≥ 17 kg will receive TDF placebo tablet administered orally once daily.~* Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF placebo oral powder once daily.
Study: NCT03566303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 15 mg
Description: Rivaroxaban 15 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Warfarin
Description: Warfarin
Study: NCT02719379

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)
Study: NCT01818674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microclinic Behavioral Health Full Program (education curriculum in classroom setting, plus full social interaction program)
Description: A 6-month intervention program (sessions and educational materials) aims to increase knowledge and skills in diabetes self-management and peer support and monitoring. The curriculum include causes of diabetes, prevention of complications, symptoms, self-management strategies, diet, exercise, peer monitoring and support by trained Project nurses from MoH health centers, local physicians, and university professors. Each class will provide 2-3 hours of discussion to foster active class participation and engagement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microclinic Behavioral Health Basic Program (education-only in classroom setting; no structured social interactions)
Description: This basic program (6 month) aims to increase participants knowledge about diabetes self-management, but without structured social interaction programming. While group classroom setting is still used for delivery of the educational curriculum, the education program in group B have no group-based or team-building activities, group goal setting, and classroom program is lecture style with more limited class participation and interaction.
Study: NCT03595930

Intervention type: DRUG
Intervention: Arnuity
Description: ARNUITY consist of Fluticasone Furoate, is an Inhaled corticosteroids (ICS) medicine taken as one inhalation, once daily, for the control and prevention of asthma in adults and children aged 12 years and older.
Study: NCT04227743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryobiopsy
Description: . The cryobiopsy samples will be obtained by advancement of the cryoprobe into the working channel of the bronchoscope to touch the tip of the endobronchial tumor. The freezing time will be approximately 4 seconds. Then, flexible bronchoscope together with tissue sample attached to the tip of the frozen probe will be extracted outside the bronchial tree. The tissue sample will be released from the probe's tip by plunging it into saline at room temperature. FB will be reintroduced after cryobiopsy to evaluate and control the bleeding.
Study: NCT02432469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APP intervention
Description: The APP contains education materials about secondary intervention of coronary artery disease, patients can surf and read them very easily. The APP also collects information on medication prescription by doctors, reminds patients at every time of taking medications, and asks for feedback from patients at 8 pm every day. The APP also pushes a patient-specific questionnaire with 10-15 questions weekly, to collect information about patients' medication adherence and self-management on blood pressure, blood lipid, blood glucose, physical activity, diet and body weight. APP pushes series of recommendations right after patients' finishing the questionnaire to help them improve their secondary prevention.
Study: NCT00661739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Dose-level Bendamustine(mg/m²): I:50; II:60; III:60; IV:70; V:70 Dose-level Paclitaxel (mg/m²): I:60; II:60; III:80; IV:80; V:90 Treatment will be given on day 1,8,15 and repeated on day 29. When the recommended dose has been determined a total of 48 pts will be treated at this dose level.
Study: NCT02417584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positive airway pressure (PAP)
Description: Positive Airway Pressure (PAP) is a non-invasive machine providing air pressure f to prevent the collapse of the oropharyngeal walls and the obstruction of airflow during sleep, which occurs in obstructive sleep apnea hypopnea syndrome.
Study: NCT03444233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: 7 days fruit-rich diet, 7 days HFCS-rich diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: 7 days fruit-rich diet, 7 days HFCS-rich diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: 7 days fruit-rich diet, 7 days HFCS-rich diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: 7 days fruit-rich diet, 7 days HFCS-rich diet
Study: NCT02236065

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Study: NCT01422525

Intervention type: PROCEDURE
Intervention: spectral domain optical coherence tomography
Description: RNFL thickness measurement using spectral domain optical coherence tomography at baseline, 1, 3 and 6 months postoperatively.
Study: NCT05100043

Intervention type: BIOLOGICAL
Intervention: IL-4 and IFN-γ measurements
Description: Blood samples are withdrawn from participants and whole blood cultures are prepared and stimulated by bivalent HPV vaccine.IL-4 and IFN-γ are measured in culture supernatants

Intervention type: BIOLOGICAL
Intervention: IL-4 and IFN-γ measurements
Description: Blood samples are withdrawn from participants and whole blood cultures are prepared and stimulated by bivalent HPV vaccine.IL-4 and IFN-γ are measured in culture supernatants
Study: NCT04251884

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic (ropivacaine)
Description: Patients randomized in the treatment arm will receive a sonography-guided pudendal nerve block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthetic (ropivacaine)
Description: Patients randomized in the treatment arm will receive a sonography-guided pudendal nerve block
Study: NCT04059692

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cervical manipulation intervention
Description: Cervical manipulative technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo intervention
Description: Sham intervention
Study: NCT04270071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitroglycerin tablets
Description: Be used when angina attack
Study: NCT01756794

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liver transplantation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liver transplantation
Study: NCT04436562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Poziotinib
Description: Single oral administration of 8 mg (as the hydrocholoride salt) of \[14C\]-poziotinib